Small Cell Lung Cancer

The AJMC® Lung Cancer compendium is a comprehensive resource for clinical news and expert insights for the condition.

Latest News

With inconclusive treatment guidance and varying findings from clinical trials, the prognosis of transformed SCLC remains poor. | Image credit: Crystal Light - stock.adobe.com
Whole Exome Sequencing Identifies Distinct Profile of Transformed SCLC

May 12th 2025

Researchers hope that identifying the genomic alterations specific to transformed small cell lung cancer (SCLC) can help drive improvements in personalized treatments for these patients.

Doctor showing lung x ray | Image credit: didesign – stock.adobe.com
Tarlatamab Safety Varies Between Clinical and Real-World SCLC Trials

May 6th 2025

Digitally generated lungs held by doctor | Image credit: Image credit: PRASANNAPIX - stock.adobe.com
Chemo Plus IO Offers Survival Benefit in ES-SCLC vs Chemo Alone in Real-World Study

April 29th 2025

Considering the life-threatening risk of TLS, the researchers underscored the importance of identifying patients at particular risk of the complication. | Image credit: mi_viri - stock.adobe.com
Optimized Strategies Needed for TLS Prevention, Intervention in SCLC

April 23rd 2025

OS was the primary end point in the trial, and data from the planned interim analysis will be presented at an upcoming scientific meeting. | Image credit: Crystal light - stock.adobe.com
Tarlatamab Improves Overall Survival in Extensive-Stage SCLC

April 14th 2025

Multidisciplinary Approaches to Paraneoplastic LEMS

Hear from medical experts as they explore the connection between Lambert-Eaton myasthenic syndrome and small cell lung cancer, discussing diagnostic challenges, economic impacts, and strategies for optimizing care.

Hear from medical experts as they explore the connection between Lambert-Eaton myasthenic syndrome and small cell lung cancer, discussing diagnostic challenges, economic impacts, and strategies for optimizing care.

More News

Doctor Looking at Scan
January 13th 2021

ACS Cancer Statistics Report Shows Record Drop in Cancer Mortality, But Persistent Disparities

Rose McNulty
The 2021 American Cancer Society annual Cancer Statistics report found that the overall rate of cancer mortality continuously declined from 1991 to 2018 but also highlighted racial and geographic disparities.
Joanna Thompson, Highlands Oncology Group
December 31st 2020

Joanna Thompson Discusses What Makes a Patient High Risk for Lung Cancer

There are several risk factors to review when determining whether or not a patient is high risk for lung cancer and should be screened, said Joanna Thompson, multidisciplinary program manager, Highlands Oncology Group.
The Top 5 Lung Cancer Stories of 2020
December 27th 2020

The Top 5 Most-Read Lung Cancer Stories of 2020

Rose McNulty
This year’s top 5 most-read stories in lung cancer were overrun by non–small cell lung cancer drug trial results and FDA action.
COVID-19 Vaccines
December 21st 2020

COVID-19 Vaccine Considerations for the Immunocompromised

Rose McNulty
FDA fact sheets on coronavirus disease 2019 (COVID-19) vaccines provide guidelines for special patient populations, including the immunocompromised.
Lung Cancer
December 17th 2020

Immunotherapy Side Effects and OS in NSCLC

Rose McNulty
NSCLC patients who developed immune-related adverse events during immunotherapy showed longer overall survival and progression-free survival than patients who did not.
Lung Health
December 11th 2020

Women Have Lower Mortality Than Men After Lung Cancer Surgery

Rose McNulty
Women had higher survival rates after lung cancer compared with men, regardless of other risk factors, in a population-based registry study from the Karolinska Instituet in Sweden.
Joanna Thompson, Highlands Oncology Group
December 10th 2020

Joanna Thompson on Engaging With PCPs for a Successful Lung Cancer Screening Program

Highlands Oncology Group has found the most success getting the word out about its lung cancer screening program by directly engaging with primary care physicians (PCPs), said Joanna Thompson of Highlands Oncology Group.
Lung Cancer
December 4th 2020

Janssen Seeks FDA Approval of Amivantamab for Metastatic NSCLC With EGFR Exon 20 Insertion Mutations

Rose McNulty
Data from the Phase I CHRYSALIS trial also support an expanded access program that makes some patients eligible for amivantamab treatment while the FDA reviews the submission.
Drug Administration
November 25th 2020

The Importance of Cancer Clinical Trials, Even in a Pandemic

Rose McNulty
Physicians and patient advocates alike are working to spread the message that it is safe to continue on the course of cancer care and participate in clinical trials during COVID-19.
Joanna Thompson, Highlands Oncology Group
November 22nd 2020

Joanna Thompson Outlines How Highlands Oncology Group Screens for Lung Cancer

The Highlands Oncology Group partners with primary care providers to identify patients at high risk of lung cancer so the specialists can do a more in-depth screening, explained Joanna Thompson, multidisciplinary program manager, Highlands Oncology Group.
Lung Cancer
November 20th 2020

First-Line Lorlatinib Improves PFS in ALK-Positive NSCLC

Rose McNulty
Early treatment with lorlatinib led to improved progression-free survival in ALK-positive NSCLC patients compared with crizotinib treatment, a study published in the New England Journal of Medicine found.
Cost Savings at Multidisciplinary Lung Clinics
November 18th 2020

Multidisciplinary Lung Cancer Clinic Saves Patients, System Costs

Rose McNulty
Multidisciplinary lung cancer clinics might help patients and the system save on treatment costs while improving patient experiences, according to an abstract presented at CHEST 2020.
Contributor: Links Between COVID-19 Comorbidities, Mortality Detailed in FAIR Health Study
November 11th 2020

Contributor: Links Between COVID-19 Comorbidities, Mortality Detailed in FAIR Health Study

Robin Gelburd, JD
In patients under age 70, lung cancer conferred the highest risk of death from coronavirus disease 2019 (COVID-19).
Lung Cancer Screening
November 9th 2020

Lung Cancer Screening Criteria Miss Young, High-Risk Black Smokers

Rose McNulty
Current lung cancer screening guidelines do not identify high-risk young, African American smokers, an abstract presented at CHEST 2020 found.
Lung Cancer Screenings
November 4th 2020

Can Emphasis on Education Increase Lung Cancer Screenings?

Rose McNulty
Abstracts presented at CHEST 2020 explored possible reasons for low lung cancer screening rates and suggested solutions.
Lung illustration
November 3rd 2020

Libtayo Accepted for FDA Priority Review in NSCLC With PD-L1 Expression

Rose McNulty
Regeneron’s PD-1 inhibitor Libtayo was accepted for priority FDA review for the treatment of first-line locally advanced or metastatic non–small cell lung cancer (NSCLC) with PD-L1 expression of at least 50%.
Lung Cancer Screenings for Women
October 31st 2020

Lung Cancer in Women: More Risk, Less Attention

Rose McNulty
Current screening criteria in the United States identify fewer women than men who will get lung cancer, creating a perfect storm for what experts during a session at the CHEST Annual Meeting deemed an “invisible epidemic.”
Non-Small Cell Lung Cancer
October 29th 2020

KRAS G12C Inhibitor Shows Promising Effects in NSCLC, Other Solid Tumors

Rose McNulty
A pair of abstracts based on a phase 1/2 trial of adagrasib (MRTX849) a KRAS G12C inhibitor, showed promising results for patients with lung, bowel, and other solid tumors, researchers reported at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
Non-Small Cell Lung Cancer Outcomes With Pembrolizumab Plus Radiation
October 23rd 2020

Pembrolizumab Plus Radiation Therapy Improves NSCLC Outcomes, Study Finds

Rose McNulty
Researchers analyzed 2 randomized studies to learn how adding radiation therapy to pembrolizumab immunotherapy affects non-small cell lung cancer patient outcomes.
Woman Consulting With a Doctor
October 22nd 2020

Cancer Care Delays in COVID-19 Could Lead to Higher Morbidity, Mortality

Rose McNulty
Cancer screenings and treatments saw a sharp decline during the early months of the pandemic. The authors of a new study on the delays in care warn that the fallout may be grim.
Propelled by Targeted Therapies, NSCLC Mortality Fell Between 2013 to 2016
October 17th 2020

Propelled by Targeted Therapies, NSCLC Mortality Fell Between 2013 to 2016

Allison Inserro
Nearly 10,000 deaths from non–small-cell lung cancer (NSCLC) were likely delayed between 2014 to 2016, the researchers calculated.
Nivolumab Meets Primary Endpoint in Resectable NSCLC
October 16th 2020

Nivolumab Meets Primary Endpoint in Resectable NSCLC

AJMC Staff
The safety profile of nivolumab plus chemotherapy was also consistent with previously reported studies in NSCLC, the researchers said.
Phase 2 Trial for Sotorasib Yields Positive Results With Certain Type of NSCLC
October 10th 2020

Phase 2 Trial for Sotorasib Yields Positive Results With Certain Type of NSCLC

Skylar Jeremias
In announcing the topline results, Amgen said that sotorasib met the primary end point of centrally assessed objective response rate.
Dr Blythe Adamson: PD-L1 as a Predictive Biomarker in Lung Cancer Continues to Evolve
October 6th 2020

Dr Blythe Adamson: PD-L1 as a Predictive Biomarker in Lung Cancer Continues to Evolve

Personalized recommendations for patients with non–small cell lung cancer with squamous histology could benefit from research on treatment choice and biomarkers, noted Blythe Adamson, PhD, MPH, principal quantitative scientist at Flatiron Health.
Atezolizumab Leads to Longer OS for Some Types of Advanced NSCLC, Study Says
September 30th 2020

Atezolizumab Leads to Longer OS for Some Types of Advanced NSCLC, Study Says

Allison Inserro
Efficacy and safety of atezolizumab as first-line therapy for metastatic non–small cell lung cancer (NSCLC) with high levels of PD-L1 expression is not known, the authors said.
Combo Treatment Bests Cemiplimab Monotherapy, Phase 2 Data Show
September 30th 2020

Combo Treatment Bests Cemiplimab Monotherapy, Phase 2 Data Show

Maggie L. Shaw
Study results presented during the virtual European Society for Medical Oncology meeting demonstrated the superiority of cemiplimab (Libtayo) plus ipilimumab vs cemiplimab monotherapy for non–small cell lung cancer.
Phase 3 Trial Results Highlight Cemiplimab’s Potential in NSCLC
September 23rd 2020

Phase 3 Trial Results Highlight Cemiplimab’s Potential in NSCLC

Maggie L. Shaw
Data from the EMPOWER-Lung 1 trial of cemiplimab (Libtayo) monotherapy vs chemotherapy show why the fully-human monoclonal antibody could become a new treatment option for non–small cell lung cancer (NSCLC).
Sotorasib Shows Benefit for Patients With Certain Type of NSCLC
September 21st 2020

Sotorasib Shows Benefit for Patients With Certain Type of NSCLC

Allison Inserro
The KRAS mutation occurs in 13% of non–small cell lung cancers (NSCLC) and leads to worse outcomes in NSCLC.
Dr Melissa Johnson: COVID-19 Has Brought About Lasting Change to Medicine
September 18th 2020

Dr Melissa Johnson: COVID-19 Has Brought About Lasting Change to Medicine

Melissa L. Johnson, MD, associate director for lung cancer research at Sarah Cannon Research Institute and partner in Tennessee Oncology, speaks on changes necessitated by the coronavirus disease 2019 (COVID-19) pandemic and connecting virtually.
Image of lung cancer
September 17th 2020

Pandemic Altered Treatment Plans for Patients With Lung Cancer, Study Finds

Allison Inserro
More than half of the patients in this study, with either non–small or small cell lung cancer, experienced changes in their treatment plan during the coronavirus disease 2019 pandemic this spring.
<1
...
5678910>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo